MCID: OLG006
MIFTS: 37

Oligoastrocytoma

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Oligoastrocytoma

MalaCards integrated aliases for Oligoastrocytoma:

Name: Oligoastrocytoma 53 59 29
Mixed Oligoastrocytoma 59 73
Mixed Oligodendroglioma-Astrocytoma 73
Oligoastrocytoma Mixed 55
Moa 59

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Orphanet 59 ORPHA251656
UMLS via Orphanet 74 C0280793
ICD10 via Orphanet 34 C71.9
UMLS 73 C0547065

Summaries for Oligoastrocytoma

NIH Rare Diseases : 53 Oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to form a mass.  These brain cells are known as glial cells, which normally protect and support nerve cells in the brain.  Because an oligoastrocytoma is made up of a combination of two cell types, it is known as a mixed glioma.  Oligoastrocytomas usually occur in a part of the brain called the cerebrum and are diagnosed in adults between the ages of 30 and 50.  The exact cause of this condition is unknown.

MalaCards based summary : Oligoastrocytoma, also known as mixed oligoastrocytoma, is related to oligodendroglioma and anaplastic oligodendroglioma, and has symptoms including headache and seizures. An important gene associated with Oligoastrocytoma is GFAP (Glial Fibrillary Acidic Protein). The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and bone marrow.

Wikipedia : 76 Oligoastrocytomas are a subset of brain tumors that present with an appearance of mixed glial cell... more...

Related Diseases for Oligoastrocytoma

Graphical network of the top 20 diseases related to Oligoastrocytoma:



Diseases related to Oligoastrocytoma

Symptoms & Phenotypes for Oligoastrocytoma

UMLS symptoms related to Oligoastrocytoma:


headache, seizures

Drugs & Therapeutics for Oligoastrocytoma

Drugs for Oligoastrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
3
Carmustine Approved, Investigational Phase 3,Not Applicable 154-93-8 2578
4
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
5
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
6
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
7
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
8
Cyproheptadine Approved Phase 3 129-03-3 2913
9
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
10 tannic acid Approved, Nutraceutical Phase 3
11 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
12 Dermatologic Agents Phase 3,Phase 1,Phase 2
13 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
14 interferons Phase 3,Phase 1,Early Phase 1
15 Gastrointestinal Agents Phase 3,Phase 1,Early Phase 1,Not Applicable
16 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
17 Antiviral Agents Phase 3,Phase 1,Early Phase 1
18 Interferon-alpha Phase 3
19 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
20
Histamine Phosphate Phase 3 51-74-1 65513
21 Serotonin Agents Phase 3
22 Serotonin Antagonists Phase 3
23 Histamine Antagonists Phase 3
24 Histamine H1 Antagonists Phase 3
25 Anti-Allergic Agents Phase 3
26 Antipruritics Phase 3
27
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
28
Iodine Approved, Investigational Phase 2 7553-56-2 807
29
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
30
Lenograstim Approved, Investigational Phase 2 135968-09-1
31
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
32
Hydroxyurea Approved Phase 2 127-07-1 3657
33
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
34
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
35
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
36
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
37
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
38
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
39
Nintedanib Approved Phase 2 656247-17-5 56843413
40
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
41
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
42
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
43
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
44
Mannitol Approved, Investigational Phase 1, Phase 2,Phase 2 69-65-8 453 6251
45
Cetuximab Approved Phase 2,Phase 1 205923-56-4 56842117 2333
46
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
47
Palbociclib Approved, Investigational Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
48
Dopamine Approved Phase 2,Not Applicable 51-61-6, 62-31-7 681
49
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
50
Acetaminophen Approved Phase 2 103-90-2 1983

Interventional clinical trials:

(show top 50) (show all 99)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
3 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
4 A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas Recruiting NCT02629757 Phase 3 β-elemene
5 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
6 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
7 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
8 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
9 A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas Unknown status NCT02209428 Phase 2 Temozolomide
10 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
11 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
12 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
13 Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
14 Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma Completed NCT00400816 Phase 2 temozolomide
15 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2 topotecan hydrochloride
16 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
17 Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Completed NCT00823459 Phase 2 RAD001
18 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
19 Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma Completed NCT00041587 Phase 1, Phase 2 IL13-PE38QQR
20 Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma Completed NCT00024570 Phase 1, Phase 2 IL13-PE38QQR
21 Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Completed NCT00615927 Phase 2 Imatinib Mesylate & Hydroxyurea
22 Bevacizumab for Recurrent Malignant Glioma Completed NCT00271609 Phase 2 Bevacizumab
23 BIBF 1120 for Recurrent High-Grade Gliomas Completed NCT01380782 Phase 2 BIBF 1120
24 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Completed NCT00995007 Phase 2 ZD6474 (Vandetanib);Carboplatin
25 Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
26 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
27 Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) Completed NCT00671970 Phase 2 Bevacizumab and Erlotinib
28 Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Recruiting NCT02530320 Phase 2 Palbociclib
29 Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors Recruiting NCT00303849 Phase 1, Phase 2 Carboplatin;Etoposide Phosphate;Mannitol;Melphalan;Sodium Thiosulfate
30 Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA Recruiting NCT02800486 Phase 2 Intra-arterial Cetuximab;Intra-arterial Mannitol
31 Everolimus With and Without Temozolomide in Adult Low Grade Glioma Recruiting NCT02023905 Phase 2 Everolimus;Temozolomide
32 Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma Recruiting NCT03180502 Phase 2 Temozolomide
33 A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas Recruiting NCT01986348 Phase 2 Selinexor
34 Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 Recruiting NCT01884740 Phase 1, Phase 2 SIACI of Erbitux and Bevacizumab
35 Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor Active, not recruiting NCT00049127 Phase 1, Phase 2 Imatinib Mesylate
36 A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas Active, not recruiting NCT02104310 Phase 2 Fluorine-18-L-dihydroxyphenylalanine
37 Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma Active, not recruiting NCT01635283 Phase 2
38 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Active, not recruiting NCT01189266 Phase 1, Phase 2 Vorinostat
39 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
40 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
41 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
42 A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Terminated NCT00389090 Phase 2 Temozolomide and O6-Benzylguanine
43 Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas Terminated NCT00062504 Phase 2 Talampanel
44 Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors Terminated NCT00848523 Phase 2 Panobinostat
45 Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) Terminated NCT01110876 Phase 1, Phase 2 Vorinostat;Erlotinib;Temozolomide
46 Trial of IDH305 in IDH1 Mutant Grade II or III Glioma Withdrawn NCT02977689 Phase 2 IDH305
47 Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme (Phase II) Withdrawn NCT02369367 Phase 2 Irinotecan;Lenalidomide
48 Phase I/II Cabazitaxel for Recurrent Malignant Glioma Withdrawn NCT01740570 Phase 1, Phase 2 Cabazitaxel
49 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
50 Sorafenib in Newly Diagnosed High Grade Glioma Completed NCT00884416 Phase 1 Sorafenib dose escalation

Search NIH Clinical Center for Oligoastrocytoma

Genetic Tests for Oligoastrocytoma

Genetic tests related to Oligoastrocytoma:

# Genetic test Affiliating Genes
1 Oligoastrocytoma 29

Anatomical Context for Oligoastrocytoma

MalaCards organs/tissues related to Oligoastrocytoma:

41
Brain, Bone, Bone Marrow, Spinal Cord, Myeloid

Publications for Oligoastrocytoma

Articles related to Oligoastrocytoma:

(show top 50) (show all 87)
# Title Authors Year
1
Multifocal and multicentric low-grade oligoastrocytoma in a young patient. ( 28523320 )
2017
2
Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity? ( 28419269 )
2017
3
Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status. ( 27796734 )
2017
4
Primary spinal cord anaplastic oligoastrocytoma presenting with paraplegia. ( 26851716 )
2016
5
Focal seizure induced by preoperative navigated transcranial magnetic stimulation in a patient with anaplastic oligoastrocytoma. ( 28017645 )
2016
6
Unique case of oligoastrocytoma with recurrence and grade progression: Exhibiting differential expression of high mobility group-A1 and human telomerase reverse transcriptase. ( 27672647 )
2016
7
Neurosurgery concepts: Key perspectives on intrathecal fluorescein for detecting intraoperative cerebrospinal fluid leak during endoscopic endonasal surgery, spinal intraarterial chemotherapy, oligoastrocytoma classification by in situ molecular genetics, and prenatal myelomeningocele closure and the need for cerebrospinal fluid shunt placement. ( 27857862 )
2016
8
A case of medulloblastoma in adult patient affected by anaplastic oligoastrocytoma. ( 27329275 )
2016
9
Primary Spinal Oligoastrocytoma. ( 27092919 )
2016
10
Combined ATRX/IDH1 immunohistochemistry predicts genotype of oligoastrocytomas. ( 26016385 )
2016
11
A rare case of oligoastrocytoma with atypical symptoms initially diagnosed as multiple sclerosis: A case report. ( 26893863 )
2016
12
Overview of Transgenic Glioblastoma and Oligoastrocytoma CNS Models and Their Utility in Drug Discovery. ( 26995546 )
2016
13
Solitary "aggressive" leptomeningeal anaplastic oligoastrocytoma. ( 26318905 )
2015
14
Opsoclonus-myoclonus syndrome in a patient with an anaplastic oligoastrocytoma. ( 25864100 )
2015
15
Does morphological assessment have a role in classifying oligoastrocytoma as "oligodendroglial" vs. "astrocytic"? ( 26466141 )
2015
16
Anaplastic oligoastrocytoma: is molecular stratification based on 1p/19q status alone appropriate? ( 25555564 )
2015
17
Primary spinal oligoastrocytoma mimicking longitudinally extensive transverse myelitis. ( 26590667 )
2015
18
Farewell to oligoastrocytoma: response to letters. ( 25381649 )
2014
19
Mixed Glioma (Oligoastrocytoma) in the Brain ofA an African Hedgehog (Atelerix albiventris). ( 25172052 )
2014
20
High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas. ( 24519516 )
2014
21
Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma. ( 25523732 )
2014
22
Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted). ( 24812135 )
2014
23
Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean radiation oncology group study 13-12. ( 25391968 )
2014
24
Successful use of metronomic vinblastine and fluorothymidine pet imaging for the management of intramedullary spinal cord anaplastic oligoastrocytoma in a child. ( 25489269 )
2014
25
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. ( 25143301 )
2014
26
Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. ( 24162809 )
2014
27
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. ( 23896377 )
2013
28
1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. ( 23486687 )
2013
29
Infratentorial low-grade oligoastrocytoma with aggressive clinical behavior in an adult: a case report with genetic characterization. ( 22752622 )
2013
30
Analysis of CIC-associated CpG-island methylation in oligoastrocytoma. ( 23521081 )
2013
31
Experiential auditory hallucinations due to chronic epileptic discharges after radiotherapy for oligoastrocytoma. ( 23774105 )
2013
32
Cerebellar low-grade oligoastrocytoma presenting with subarachnoid haemorrhage. ( 22665014 )
2012
33
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. ( 22588899 )
2012
34
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. ( 21069360 )
2011
35
Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. ( 20556480 )
2011
36
Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination. ( 19876600 )
2010
37
Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a useful strategy to maximize surgical resection -case report-. ( 20505301 )
2010
38
Anaplastic oligoastrocytoma in Turcot syndrome. ( 19495563 )
2009
39
Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma. ( 19225409 )
2009
40
Oligoastrocytoma of the brain in a hooded crane (Grus monacha). ( 19261644 )
2009
41
Multi-focal cerebral oligoastrocytoma in a puppy. ( 19689673 )
2009
42
Autoimmunity manifesting as dermatomyositis associated with oligoastrocytoma and dendritic cell immunotherapy. ( 18443006 )
2008
43
A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. ( 18317968 )
2008
44
Anaplastic oligodendroglioma and oligoastrocytoma. ( 17964027 )
2007
45
Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. ( 17431544 )
2007
46
Malignant transformation of oligoastrocytoma: a case report. ( 18095133 )
2007
47
Anaplastic oligoastrocytoma: previous treatment as a possible cause in a child with acute lymphoblastic leukemia. ( 17043901 )
2007
48
Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma. ( 18077983 )
2007
49
Oligoastrocytoma presenting with intractable epilepsy. ( 17884756 )
2007
50
Isolation and characterization of stem cell-like precursor cells from primary human anaplastic oligoastrocytoma. ( 17660801 )
2007

Variations for Oligoastrocytoma

Expression for Oligoastrocytoma

Search GEO for disease gene expression data for Oligoastrocytoma.

Pathways for Oligoastrocytoma

GO Terms for Oligoastrocytoma

Sources for Oligoastrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....